{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:16:13Z","timestamp":1788441373729,"version":"build-2803163510"},"reference-count":62,"publisher":"IMR Press","issue":"8","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Future Academic Star of Guangxi Medical University","award":["WLXSZX26B029"],"award-info":[{"award-number":["WLXSZX26B029"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Background:Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. However, the role of small ubiquitin-like modifier 2 (SUMO2), a core member of the small ubiquitin-like modifier (SUMO) family, regarding its expression patterns and metabolism-related functions in HCC remains inadequately understood.Methods:A multidimensional analytical framework was applied, integrating immunohistochemistry (153 HCC vs. 21 non-HCC samples), proteomics (159 paired samples), bulk transcriptomics (3240 HCC vs. 2267 non-HCC samples), single-cell RNA sequencing (RNA-seq) (10 HCC vs. 8 non-HCC samples), spatial transcriptomics, and external CRISPR\/Cas9 functional genomics data. Systematic analyses included standardized mean difference (SMD), pathway enrichment, pseudotime trajectory inference, in silico knockout, cell\u2013cell communication, metabolic flux scoring, immune infiltration, clinical correlation, drug sensitivity prediction, and molecular docking.Results:At the protein level, immunohistochemistry (nuclear positivity) and external proteomic data collectively demonstrated consistent SUMO2 overexpression in HCC. Consistent upregulation was also observed at the mRNA level across large-scale cohorts. Single-cell RNA-seq and spatial transcriptomics localized SUMO2 enrichment to malignant hepatocytes and tumor-dominant regions. CRISPR-mediated SUMO2 knockout suppressed proliferation in multiple HCC cell lines. Mechanistically, high SUMO2 expression was significantly associated with metabolic reprogramming involving glycolysis\/gluconeogenesis, pyruvate metabolism, and the tricarboxylic acid cycle. SUMO2-high malignant hepatocyte subpopulations exhibited enhanced activity of the macrophage migration inhibitory factor signaling axis and enhanced iron-sensor interactions. Further, the immune infiltration analysis revealed a negative correlation between SUMO2 expression and M1 macrophages and a positive correlation between follicular helper T cells and regulatory T cells. Clinically, elevated SUMO2 levels were found to be associated with adverse prognostic features. Furthermore, high SUMO2 expression was associated with increased sensitivity to dasatinib, and molecular docking simulations predicted potential binding between SUMO2 and dasatinib, with a Vina score of \u22128.5 kcal\/mol.Conclusions:SUMO2 is aberrantly expressed at the protein, mRNA, single-cell, and spatial transcriptomic levels in HCC and is significantly associated with metabolic reprogramming and altered migration inhibitory factor (MIF)-mediated intercellular communication, suggesting its potential as a novel biomarker for diagnosis and treatment.<\/jats:p>","DOI":"10.31083\/fbl52385","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:35:31Z","timestamp":1788438931000},"source":"Crossref","is-referenced-by-count":0,"title":["Multimodal Analysis Reveals Aberrant Expression of SUMO2 and Its Significant Association With Key Mechanisms of Metabolic Pathways in Hepatocellular Carcinoma"],"prefix":"10.31083","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5314-2576","authenticated-orcid":true,"given":"Yulong","family":"Deng","sequence":"first","affiliation":[{"name":"Research Department, Affiliated Cancer Hospital, Guangxi Medical University, 530021 Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4392-1272","authenticated-orcid":true,"given":"Beibei","family":"Huang","sequence":"additional","affiliation":[{"name":"Research Department, Affiliated Cancer Hospital, Guangxi Medical University, 530021 Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4382-4942","authenticated-orcid":true,"given":"Yuxing","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3719-8953","authenticated-orcid":true,"given":"Qinyan","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6667-5578","authenticated-orcid":true,"given":"Hongquan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7835-0211","authenticated-orcid":true,"given":"Hongbo","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8425-4684","authenticated-orcid":true,"given":"Huanhuan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1232-358X","authenticated-orcid":true,"given":"Kunhua","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6707-4998","authenticated-orcid":true,"given":"Shipei","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2106-5896","authenticated-orcid":true,"given":"Yiwu","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2402-2987","authenticated-orcid":true,"given":"Gang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9881-7320","authenticated-orcid":true,"given":"Minhua","family":"Rong","sequence":"additional","affiliation":[{"name":"Research Department, Affiliated Cancer Hospital, Guangxi Medical University, 530021 Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Sato-Espinoza K, Valdivia-Herrera M, Chotiprasidhi P, Diaz-Ferrer J. Hepatocellular carcinoma in patients without cirrhosis. World Journal of Gastroenterology. 2025; 31: 107100.","DOI":"10.3748\/wjg.v31.i23.107100"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Moris D, Martinino A, Schiltz S, Allen PJ, Barbas A, Sudan D, et al. Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians. CA: a Cancer Journal for Clinicians. 2025; 75: 498\u2013527.","DOI":"10.3322\/caac.70018"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Tabrizian P, Pero A, Schwartz M. Hepatic Resection for Hepatocellular Carcinoma. Clinics in Liver Disease. 2025; 29: 59\u201372.","DOI":"10.1016\/j.cld.2024.08.008"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Zhong BY, Fan W, Guan JJ, Peng Z, Jia Z, Jin H, et al. Combination locoregional and systemic therapies in hepatocellular carcinoma. The Lancet. Gastroenterology & Hepatology. 2025; 10: 369\u2013386.","DOI":"10.1016\/S2468-1253(24)00247-4"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Singal AG, Salem R, Pinato DJ, Pillai A. Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma. Gastroenterology. 2025; 169: 585\u2013599.","DOI":"10.1053\/j.gastro.2025.03.047"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Sharma KK, Mohsin M, Mittal P, Ali Z, Fatma N, Upadhyay P, et al. Diagnosis of the Initial Stage of Hepatocellular Carcinoma: A Review. Current Pharmaceutical Design. 2024; 30: 1708\u20131724.","DOI":"10.2174\/0113816128298875240321073907"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Yang W, Nguyen R, Safri F, Shiddiky MJA, Warkiani ME, George J, et al. Liquid Biopsy in Hepatocellular Carcinoma: ctDNA as a Potential Biomarker for Diagnosis and Prognosis. Current Oncology Reports. 2025; 27: 791\u2013802.","DOI":"10.1007\/s11912-025-01681-3"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Zheng W, Haw Y, Wang HL. Advances in Hepatocellular Carcinoma: Molecular Insights, Histologic Subtypes, and Differential Diagnosis. Advances in Anatomic Pathology. 2025; 32: 317\u2013326.","DOI":"10.1097\/PAP.0000000000000501"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Liao Z, Steenwinkel TE, Moscoso B, Salas E, Patton BK, Rodriguez A, et al. Disruption of oocyte SUMOylation impacts critical regulatory processes during folliculogenesis in mice\u2020. Biology of Reproduction. 2025; 112: 932\u2013941.","DOI":"10.1093\/biolre\/ioaf035"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Chen Y, Chang L, Hu L, Yan C, Dai L, Shelat VG, et al. Identification of a lactylation-related gene signature to characterize subtypes of hepatocellular carcinoma using bulk sequencing data. Journal of Gastrointestinal Oncology. 2024; 15: 1636\u20131646.","DOI":"10.21037\/jgo-24-405"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Chen J, Chen C, Lin Y, Su Y, Yu X, Jiang Y, et al. Downregulation of SUMO2 inhibits hepatocellular carcinoma cell proliferation, migration and invasion. FEBS Open Bio. 2021; 11: 1771\u20131784.","DOI":"10.1002\/2211-5463.13173"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Khai NX, Huy DQ, Trang DT, Minh NT, Tien TD, Phuong NV, et al. Expression of SUMO and NF-\u03baB genes in hepatitis B virus-associated hepatocellular carcinoma patients: An observational study. Medicine. 2024; 103: e38737.","DOI":"10.1097\/MD.0000000000038737"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Liu Y, Wang X, Zeng X, Wu Y, Liu X, Tan J, et al. Bioinformatics-based analysis of SUMOylation-related genes in hepatocellular carcinoma reveals a role of upregulated SAE1 in promoting cell proliferation. Open Medicine (Warsaw, Poland). 2022; 17: 1183\u20131202.","DOI":"10.1515\/med-2022-0510"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Liu J, Li X, Chen J, Guo J, Guo H, Zhang X, et al. Targeting SUMOylation with an injectable nanocomposite hydrogel to optimize radiofrequency ablation therapy for hepatocellular carcinoma. Journal of Nanobiotechnology. 2024; 22: 338.","DOI":"10.1186\/s12951-024-02579-1"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Shen Y, Ye B, Li C. SUMO2 inhibits ACSL3 protein degradation to antagonize erastin-induced ferroptosis in hepatocellular carcinoma. Discover Oncology. 2025; 16: 1131.","DOI":"10.1007\/s12672-025-02921-5"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Peng Z, Wang S, Wen D, Mei Z, Zhang H, Liao S, et al. FEN1 upregulation mediated by SUMO2 via antagonizing proteasomal degradation promotes hepatocellular carcinoma stemness. Translational Oncology. 2024; 44: 101916.","DOI":"10.1016\/j.tranon.2024.101916"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Liu C, Xu K, Liu J, He C, Liu P, Fu Q, et al. LncRNA RP11-620J15.3 promotes HCC cell proliferation and metastasis by targeting miR-326\/GPI to enhance glycolysis. Biology Direct. 2023; 18: 15.","DOI":"10.1186\/s13062-023-00370-0"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Lu M, Wu Y, Xia M, Zhang Y. The role of metabolic reprogramming in liver cancer and its clinical perspectives. Frontiers in Oncology. 2024; 14: 1454161.","DOI":"10.3389\/fonc.2024.1454161"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Yang Y, Gao Y, Xiong Y, Gong Y, Lu J, Zhang Y, et al. Research Progress of Warburg Effect in Hepatocellular Carcinoma. Frontiers in Bioscience (Landmark Edition). 2024; 29: 178.","DOI":"10.31083\/j.fbl2905178"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Zeng DT, Chen ZY, Li ZYM, Chi BT, Li JD, Zhang W, et al. The Role and Mechanism of G Protein Subunit Alpha-15 in Colorectal Cancer: An Analysis of Two Hundred Eight Patient Samples and Public Datasets. World Journal of Oncology. 2026; 17: 116\u2013128.","DOI":"10.14740\/wjon2647"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Chen ZD, Lu HP, Zhan YT, He FY, Zhu LQ, Deng YL, et al. Overexpression, clinical significance and potential mechanisms of protein kinase D1 in hepatocellular carcinoma: multi-omic analyses and pharmacological insights. Functional & Integrative Genomics. 2026; 26: 37.","DOI":"10.1007\/s10142-026-01825-z"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Jiang S, Lu H, Pan Y, Yang A, Aikemu A, Li H, et al. Characterization of the distinct immune microenvironments between hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Letters. 2024; 588: 216799.","DOI":"10.1016\/j.canlet.2024.216799"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Virshup I, Bredikhin D, Heumos L, Palla G, Sturm G, Gayoso A, et al. The scverse project provides a computational ecosystem for single-cell omics data analysis. Nature Biotechnology. 2023; 41: 604\u2013606.","DOI":"10.1038\/s41587-023-01733-8"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Gulati GS, Sikandar SS, Wesche DJ, Manjunath A, Bharadwaj A, Berger MJ, et al. Single-cell transcriptional diversity is a hallmark of developmental potential. Science (New York, N.Y.). 2020; 367: 405\u2013411.","DOI":"10.1126\/science.aax0249"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Osorio D, Zhong Y, Li G, Xu Q, Yang Y, Tian Y, et al. scTenifoldKnk: An efficient virtual knockout tool for gene function predictions via single-cell gene regulatory network perturbation. Patterns (New York, N.Y.). 2022; 3: 100434.","DOI":"10.1016\/j.patter.2022.100434"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Xiong K, Fang Y, Qiu B, Chen C, Huang N, Liang F, et al. Investigation of cellular communication and signaling pathways in tumor microenvironment for high TP53-expressing osteosarcoma cells through single-cell RNA sequencing. Medical Oncology (Northwood, London, England). 2024; 41: 93.","DOI":"10.1007\/s12032-024-02318-4"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Zheng R, Zhang Y, Tsuji T, Gao X, Shamsi F, Wagner A, et al. MEBOCOST maps metabolite-mediated intercellular communications using single-cell RNA-seq. Nucleic Acids Research. 2025; 53: gkaf569.","DOI":"10.1093\/nar\/gkaf569"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Wu Y, Yang S, Ma J, Chen Z, Song G, Rao D, et al. Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level. Cancer Discovery. 2022; 12: 134\u2013153.","DOI":"10.1158\/2159-8290.CD-21-0316"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Alghamdi N, Chang W, Dang P, Lu X, Wan C, Gampala S, et al. A graph neural network model to estimate cell-wise metabolic flux using single-cell RNA-seq data. Genome Research. 2021; 31: 1867\u20131884.","DOI":"10.1101\/gr.271205.120"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Li C, Shao X, Zhang S, Wang Y, Jin K, Yang P, et al. scRank infers drug-responsive cell types from untreated scRNA-seq data using a target-perturbed gene regulatory network. Cell Reports. Medicine. 2024; 5: 101568.","DOI":"10.1016\/j.xcrm.2024.101568"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Ru B, Huang J, Zhang Y, Aldape K, Jiang P. Estimation of cell lineages in tumors from spatial transcriptomics data. Nature Communications. 2023; 14: 568.","DOI":"10.1038\/s41467-023-36062-6"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nature Genetics. 2017; 49: 1779\u20131784.","DOI":"10.1038\/ng.3984"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Sannigrahi MK, Cao AC, Rajagopalan P, Sun L, Brody RM, Raghav L, et al. A novel pipeline for prioritizing cancer type-specific therapeutic vulnerabilities using DepMap identifies PAK2 as a target in head and neck squamous cell carcinomas. Molecular Oncology. 2024; 18: 336\u2013349.","DOI":"10.1002\/1878-0261.13558"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Liu Z, Liu L, Weng S, Xu H, Xing Z, Ren Y, et al. BEST: a web application for comprehensive biomarker exploration on large-scale data in solid tumors. Journal of Big Data. 2023; 10: 165.","DOI":"10.1186\/s40537-023-00844-y"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Tang YX, Pang YY, Cui Y, Wu GJ, Huang LQ, Zhou CZ, et al. Molecular mechanism and biological pathway of high-expressed RAD51 in regulating cell adhesion and potentially affecting oral squamous cell carcinoma. Discover Oncology. 2025; 16: 1260.","DOI":"10.1007\/s12672-025-03085-y"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Das J, Barman B, Sarma P, Das BK, Chetia R, Kalita PP. Signalling pathways in hepatocellular carcinoma (HCC) metastasis and invasion: Molecular mechanisms and therapeutic implications. Biochemistry and Biophysics Reports. 2025; 45: 102403.","DOI":"10.1016\/j.bbrep.2025.102403"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Feng D, He J, Yuan M, Chen Q, Zeng X, Zhou Q, et al. SUMO2\/3 promotes the progression and oxaliplatin resistance of colorectal cancer through facilitating the SUMOylation at Ku80-K307. BioFactors (Oxford, England). 2023; 49: 1158\u20131173.","DOI":"10.1002\/biof.1984"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Yang H, Gao S, Chen J, Lou W. UBE2I promotes metastasis and correlates with poor prognosis in hepatocellular carcinoma. Cancer Cell International. 2020; 20: 234.","DOI":"10.1186\/s12935-020-01311-x"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Wang P, Xue N, Zhang C, Shan S, Jiang Z, Wu W, et al. Inhibition of SUMO2\/3 antagonizes isoflurane-induced cancer-promoting effect in hepatocellular carcinoma Hep3B cells. Oncology Letters. 2021; 21: 274.","DOI":"10.3892\/ol.2021.12535"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Lin J, Rao D, Zhang M, Gao Q. Metabolic reprogramming in the tumor microenvironment of liver cancer. Journal of Hematology & Oncology. 2024; 17: 6.","DOI":"10.1186\/s13045-024-01527-8"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Mao Y, Xia Z, Xia W, Jiang P. Metabolic reprogramming, sensing, and cancer therapy. Cell Reports. 2024; 43: 115064.","DOI":"10.1016\/j.celrep.2024.115064"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Li L, Xu H, Qu L, Xu K, Liu X. Daidzin inhibits hepatocellular carcinoma survival by interfering with the glycolytic\/gluconeogenic pathway through downregulation of TPI1. BioFactors (Oxford, England). 2022; 48: 883\u2013896.","DOI":"10.1002\/biof.1826"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Fang Y, Gu Y, Xu T, Wang P, Wu X, Shen H, et al. SENP1 drives glycolysis and cisplatin resistance in gastric cancer via desumoylating ENO1. Journal of Experimental & Clinical Cancer Research : CR. 2025; 44: 285.","DOI":"10.1186\/s13046-025-03543-z"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Valdez CN, S\u00e1nchez-Zuno GA, Bucala R, Tran TT. Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (DDT): Pathways to Tumorigenesis and Therapeutic Opportunities. International Journal of Molecular Sciences. 2024; 25: 4849.","DOI":"10.3390\/ijms25094849"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Thavayogarajah T, Sinitski D, El Bounkari O, Torres-Garcia L, Lewinsky H, Harjung A, et al. CXCR4 and CD74 together enhance cell survival in response to macrophage migration-inhibitory factor in chronic lymphocytic leukemia. Experimental Hematology. 2022; 115: 30\u201343.","DOI":"10.1016\/j.exphem.2022.08.005"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Xiao Y, Hu F, Chi Q. Single-cell RNA sequencing and spatial transcriptome reveal potential molecular mechanisms of lung cancer brain metastasis. International Immunopharmacology. 2024; 140: 112804.","DOI":"10.1016\/j.intimp.2024.112804"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Chen W, Yu X, Li H, Yuan S, Fu Y, Hu H, et al. Single-cell RNA-seq reveals MIF-(CD74 + CXCR4) dependent inhibition of macrophages in metastatic papillary thyroid carcinoma. Oral Oncology. 2024; 148: 106654.","DOI":"10.1016\/j.oraloncology.2023.106654"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Cheng J, Li J, Jiang X, Ma X, Li B, Zhai H, et al. CD74 facilitates immunotherapy response by shaping the tumor microenvironment of hepatocellular carcinoma. Molecular Medicine (Cambridge, Mass.). 2024; 30: 116.","DOI":"10.1186\/s10020-024-00884-x"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Xie P, Yan J, Wu M, Li H, Chen Z, Yu M, et al. CD44 potentiates hepatocellular carcinoma migration and extrahepatic metastases via the AKT\/ERK signaling CXCR4 axis. Annals of Translational Medicine. 2022; 10: 689.","DOI":"10.21037\/atm-22-2482"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Rah B, Farhat NM, Hamad M, Muhammad JS. JAK\/STAT signaling and cellular iron metabolism in hepatocellular carcinoma: therapeutic implications. Clinical and Experimental Medicine. 2023; 23: 3147\u20133157.","DOI":"10.1007\/s10238-023-01047-8"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Zheng J, Liu Y, Zhu F, Liu S, Cai Z, Liu M, et al. Picropodophyllin induces ferroptosis via blockage of AKT\/NRF2\/SLC7A11 and AKT\/NRF2\/SLC40A1 axes in hepatocellular carcinoma as a natural IGF1R inhibitor. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology. 2025; 143: 156840.","DOI":"10.1016\/j.phymed.2025.156840"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Zhang Y, Zou L, Li X, Guo L, Hu B, Ye H, et al. SLC40A1 in iron metabolism, ferroptosis, and disease: A review. WIREs Mechanisms of Disease. 2024; 16: e1644.","DOI":"10.1002\/wsbm.1644"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Adachi M, Kai K, Yamaji K, Ide T, Noshiro H, Kawaguchi A, et al. Transferrin receptor 1 overexpression is associated with tumour de-differentiation and acts as a potential prognostic indicator of hepatocellular carcinoma. Histopathology. 2019; 75: 63\u201373.","DOI":"10.1111\/his.13847"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Lai Y, Han X, Xie B, Xu Y, Yang Z, Wang D, et al. EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2. Cancer Science. 2024; 115: 2220\u20132234.","DOI":"10.1111\/cas.16186"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Wang J, He Y, Hu F, Hu C, Sun Y, Yang K, et al. Metabolic Reprogramming of Immune Cells in the Tumor Microenvironment. International Journal of Molecular Sciences. 2024; 25: 12223.","DOI":"10.3390\/ijms252212223"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Liu Y, Zhao Y, Song H, Li Y, Liu Z, Ye Z, et al. Metabolic reprogramming in tumor immune microenvironment: Impact on immune cell function and therapeutic implications. Cancer Letters. 2024; 597: 217076.","DOI":"10.1016\/j.canlet.2024.217076"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Zheng L, Wu D, Xie H, Zhao H. Revisiting Tregs in cancer and beyond: immunological control and therapeutic potential. Frontiers in Immunology. 2025; 16: 1581093.","DOI":"10.3389\/fimmu.2025.1581093"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Guti\u00e9rrez-Melo N, Baumjohann D. T follicular helper cells in cancer. Trends in Cancer. 2023; 9: 309\u2013325.","DOI":"10.1016\/j.trecan.2022.12.007"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Bai X, Guo YR, Zhao ZM, Li XY, Dai DQ, Zhang JK, et al. Macrophage polarization in cancer and beyond: from inflammatory signaling pathways to potential therapeutic strategies. Cancer Letters. 2025; 625: 217772.","DOI":"10.1016\/j.canlet.2025.217772"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Li M, Yang Y, Xiong L, Jiang P, Wang J, Li C. Metabolism, metabolites, and macrophages in cancer. Journal of Hematology & Oncology. 2023; 16: 80.","DOI":"10.1186\/s13045-023-01478-6"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Strusi G, Suelzu CM, Weldon S, Giffin J, M\u00fcnsterberg AE, Bao Y. Combination of Phenethyl Isothiocyanate and Dasatinib Inhibits Hepatocellular Carcinoma Metastatic Potential through FAK\/STAT3\/Cadherin Signalling and Reduction of VEGF Secretion. Pharmaceutics. 2023; 15: 2390.","DOI":"10.3390\/pharmaceutics15102390"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Strusi G, Suelzu CM, Horwood N, M\u00fcnsterberg AE, Bao Y. Phenethyl isothiocyanate and dasatinib combination synergistically reduces hepatocellular carcinoma growth via cell cycle arrest and oxeiptosis. Frontiers in Pharmacology. 2023; 14: 1264032.","DOI":"10.3389\/fphar.2023.1264032"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/8\/10.31083\/FBL52385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:36:01Z","timestamp":1788438961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/8\/10.31083\/FBL52385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":62,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(26)02244-6"],"URL":"https:\/\/doi.org\/10.31083\/fbl52385","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"52385"}}